Martin Kankam

1.1k total citations · 1 hit paper
34 papers, 824 citations indexed

About

Martin Kankam is a scholar working on Infectious Diseases, Molecular Biology and Epidemiology. According to data from OpenAlex, Martin Kankam has authored 34 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Infectious Diseases, 8 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Martin Kankam's work include Chronic Lymphocytic Leukemia Research (5 papers), Antimicrobial Resistance in Staphylococcus (4 papers) and Clostridium difficile and Clostridium perfringens research (4 papers). Martin Kankam is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Antimicrobial Resistance in Staphylococcus (4 papers) and Clostridium difficile and Clostridium perfringens research (4 papers). Martin Kankam collaborates with scholars based in United States, Denmark and Switzerland. Martin Kankam's co-authors include Domenica Rubino, Michael Lund, David C.W. Lau, Altynai Satylganova, Filip Dubovsky, Therese Takas, M. Pamela Griffin, Kathryn Jensen, Anis A. Khan and Tonya Villafana and has published in prestigious journals such as The Lancet, The Journal of Clinical Endocrinology & Metabolism and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Martin Kankam

34 papers receiving 804 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

2021 215 citations Martin Kankam, Michael Lund et al. The Lancet profile →

Peers

Countries citing papers authored by Martin Kankam

Since Specialization

Citations

This map shows the geographic impact of Martin Kankam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Kankam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Kankam more than expected).

Fields of papers citing papers by Martin Kankam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Kankam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Kankam. The network helps show where Martin Kankam may publish in the future.

Co-authorship network of co-authors of Martin Kankam

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Kankam. A scholar is included among the top collaborators of Martin Kankam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Kankam. Martin Kankam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans 2025 ·Molecular Metabolism ·(unknown), Jonathan D. Douros, Ronald Goldwater, Ann Maria Kruse Hansen, Julie Hjerpsted, (unknown), Martin Kankam, Patrick J. Knerr, Anish Konkar, Stephanie A. Mowery, Timo D. Müller, (unknown), Sune Boris Nygård, Diego Pérez–Tilve, Kirsten Raun, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi	6
2	A Bioequivalence Study of Two Formulations of Oral Semaglutide in Healthy Participants 2024 ·Diabetes Therapy ·Mette S. Nielsen, Lise Brøndsted, Martin Kankam, (unknown), (unknown), Trine Vang Skjøth, (unknown), (unknown)	3
3	Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity 2023 ·Molecular Metabolism ·Martin Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård	27
4	Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study 2022 ·Allergy ·Diego Alvarado, Marcus Maurer, Richard Gedrich, Scott B. Seibel, Michael Murphy, (unknown), J. Goldstein, Andrea Crocker, Laura Vitale, (unknown), Lawrence J. Thomas, Thomas Hawthorne, Tibor Keler, Diane Young, Elizabeth Crowley, Martin Kankam, Margo Heath‐Chiozzi	62
5	AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study 2022 ·ERJ Open Research ·Hunter Gillies, Ralph W. Niven, Benjamin T. Dake, Murali M. Chakinala, Jeremy P. Feldman, Nicholas S. Hill, Marius M. Hoeper, Marc Humbert, Vallerie V. McLaughlin, Martin Kankam	21
6	Pharmacokinetics and Safety of Vibegron 75 mg Administered as an Intact or Crushed Tablet in Healthy Adults 2022 ·Clinical Pharmacology in Drug Development ·(unknown), (unknown), (unknown), Cornelia Haag‐Molkenteller, Martin Kankam	10
7	Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial breakdown → 2021 ·The Lancet ·(unknown), (unknown), Martin Kankam, Michael Lund, Domenica Rubino, Altynai Satylganova, David C.W. Lau	215
8	Transition from Syringe to Autoinjector Based on Bridging Pharmacokinetics and Pharmacodynamics of the P2Y12 Receptor Antagonist Selatogrel in Healthy Subjects 2021 ·Clinical Pharmacokinetics ·Isabelle Zenklusen, (unknown), (unknown), Martin Kankam, Andreas Krause, Mike Ufer, Jasper Dingemanse	3
9	A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers 2021 ·Antimicrobial Agents and Chemotherapy ·Martin Kankam, Jennifer Burns, Marc S. Collett, Michael L. Corrado, (unknown)	11
10	Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects 2020 ·Advances in Therapy ·Martin Kankam, (unknown), Jeffrey Price, Josée Michaud, Wei Liang, (unknown), Ana Pardo Sanz, Bradley Vince, (unknown)	1
11	<p>Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects</p> 2019 ·Drug Design Development and Therapy ·Patricia N. Sidharta, Meggane Melchior, Martin Kankam, Jasper Dingemanse	34
12	A First-in-Human Study To Assess the Safety and Pharmacokinetics of LYS228, a Novel Intravenous Monobactam Antibiotic in Healthy Volunteers 2019 ·Antimicrobial Agents and Chemotherapy ·Megan Boysen‐Osborn, (unknown), Haiying Sun, Johanne Blais, Vinay Kumar Venishetty, (unknown), Martin Kankam, Richard A. Colvin, (unknown)	6
13	Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite 2019 ·British Journal of Clinical Pharmacology ·Jianke Li, Martin Kankam, Denise Trone, Guy Gammon	22
14	A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers 2017 ·Biologicals ·Raburn M. Mallory, Omar Ali, Therese Takas, Martin Kankam, Filip Dubovsky, Leo Tseng	18
15	Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults 2016 ·Antimicrobial Agents and Chemotherapy ·M. Pamela Griffin, Anis A. Khan, Mark T. Esser, Kathryn Jensen, Therese Takas, Martin Kankam, Tonya Villafana, Filip Dubovsky	113
16	Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study 2016 ·Vaccine ·Robert W. Frenck, C. Buddy Creech, Eric Sheldon, David Seiden, Martin Kankam, James Baber, Edward T. Zito, Robin Hubler, Joseph Eiden, Joseph M. Severs, Shite Sebastian, Jasdeep S. Nanra, Kathrin U. Jansen, William C. Gruber, Annaliesa S. Anderson, Douglas Girgenti	51
17	Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial 2016 ·Vaccine ·C. Buddy Creech, Robert W. Frenck, Eric Sheldon, David Seiden, Martin Kankam, Edward T. Zito, Douglas Girgenti, Joseph M. Severs, Frederick W. Immermann, Lisa K. McNeil, David Cooper, Kathrin U. Jansen, William C. Gruber, Joseph Eiden, Annaliesa S. Anderson, James Baber	43
18	An open‐label study in healthy men to evaluate the risk of seminal fluid transmission of denosumab to pregnant partners 2015 ·British Journal of Clinical Pharmacology ·Winnie Sohn, Edward Lee, Martin Kankam, Ogo Egbuna, Graeme J. Moffat, Jeanine L. Bussiere, Desmond Padhi, (unknown), (unknown), J. Greg Slatter	7
19	The Effects of Reprocessing Cuprophane and Polysulfone Dialyzers on β2-Microglobulin Removal From Hemodialysis Patients 1991 ·American Journal of Kidney Diseases ·Jeffrey Petersen, Roscoe M. Moore, Ronald G. Kaczmarek, (unknown), (unknown), (unknown), Martin Kankam	19
20	Knowledge in Relation to Cadaveric Kidney Donation in Urban Blacks 1990 ·Journal of Health Care for the Poor and Underserved ·Martin Kankam, (unknown), Roscoe M. Moore, Ronald G. Kaczmarek, (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact